Optimer Pharmaceuticals Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. The company is currently focused on the development of products that treat gastrointestinal (GI) infections and related diseases where current therapies have limitations, including diminished efficacy, serious adverse side effects, drug-to-drug interactions, difficult patient compliance and bacterial resistance. Optimer has two late-stage anti-infective product candidates, Difimicin and Prulifloxacin. Difimicin (OPT-80) is an antibiotic currently in a phase III registration trial for the treatment of Clostridium difficile-associated diarrhea (CDAD), the most common nosocomial, or hospital-acquired, diarrhea. Prulifloxacin is an antibiotic currently in two phase III trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Optimer is also developing additional product candidates using its proprietary technology, including Optimer One-Pot Synthesis (OPopS) drug discovery platform. The following table summarizes the major clinical/preclinical drug candidates:
Prevention of VRE bloodstream infections
Respiratory tract infections
Planning Phase II
In February, 2007, Optimer went public by issuing 7 million shares of common stock at a price of $7.00 per share, resulting in aggregate proceeds of approximately $43.6 million, net of underwriting discounts and commissions and offering expenses. In addition, in February 2007, the underwriters exercised in full the over-allotment option to purchase an additional 1.1 million shares of the company's common stock from a selling stockholder.
Optimer was incorporated in Delaware in November, 1998 and is headquartered in San Diego, California. Optimer has a wholly owned subsidiary, Optimer Biotechnology, Inc., in Taiwan.